Our mission is to be a leader in establishing minimally-invasive transcatheter heart valve implantation devices to treat valvular heart disease. Our safe and intuitive aortic heart valve replacement systems alleviate the burden of disease of high-risk patients suffering from severe aortic stenosis. Our devices give physicians greater control during delicate surgical interventions, and result in superb patient outcomes.

Symetis has developed exceptionally easy to use, intuitive transcatheter delivery systems with a flexible shaft and ergonomic design that allow for a controlled, sheathless, 2-step implantation. The systems’ intelligent design results in a short learning curve for physicians, and safe procedures for patients.

The ACURATE TA transapical aortic bioprosthesis consists of three non-coronary native porcine leaflets attached to a self-expanding nitinol stent and a PET skirt sutured onto the inner and the outer surface of the stent. It is self-seating and self-sealing, allows for optimal positioning of the valve, and reduces paravalvular leak.

The ACURATE neo™ transfemoral aortic bioprosthesis is composed of a porcine pericardial tissue valve sutured within a self-expanding nitinol stent covered by a pericardial skirt on the outer and inner surface of the stent body. ACURATE neo is self-seating and self-sealing, allows for optimal positioning of the valve, and reduces paravalvular leak.